SS Innovations International completed the world’s first telesurgery using its SSi Mantra Tele Surgeon Console (TSC) on October 17, 2025. Dr. Sudhir Srivastava performed a robotic‑assisted coronary artery bypass from his home in New Delhi while the patient was treated at Manipal Hospital in Jaipur, 185 miles away. The console’s chair‑based design, 3‑D visualization, and magnetic‑sensor controls enabled the surgeon to operate without a full operating‑room setup, demonstrating the feasibility of remote robotic procedures in low‑infrastructure settings.
The TSC is a scaled‑down version of SS Innovations’ flagship Mantra system. Its lightweight, compact form factor allows it to be installed in a physician’s office or a small clinical space, reducing the capital and operational costs that typically accompany larger robotic platforms. The successful procedure validates the console’s clinical reliability and positions the company to expand telesurgery services in markets where traditional robotic systems are financially out of reach.
In its most recent quarterly report, SS Innovations posted revenue of $12.83 million for the third quarter of 2025, a 193% increase from $4.39 million in the same period a year earlier. The company’s net loss narrowed to $3.72 million from $17.23 million in Q3 2024, reflecting stronger top‑line growth and improved cost management. Revenue is heavily concentrated in India, accounting for 94% of the quarter’s sales, underscoring the company’s focus on the Indian market while it seeks to broaden its global footprint.
Despite the revenue surge, SS Innovations disclosed a “substantial doubt” about its ability to continue as a going concern. The company remains reliant on financing inflows, including convertible notes, to sustain operations. The narrowing loss signals progress, but the ongoing cash burn and high leverage highlight the financial headwinds that investors and stakeholders must monitor.
The telesurgery milestone, coupled with the company’s quarterly performance, underscores a dual narrative: a technological breakthrough that could open new revenue streams, and a financial trajectory that still requires significant capital to reach profitability. SS Innovations plans to submit a 510(k) pre‑market notification to the U.S. Food and Drug Administration in Q4 2025 for multiple specialty indications, with clearance expected in the first half of 2026. The company’s strategy hinges on scaling the TSC’s adoption in emerging markets while pursuing regulatory approvals that will broaden its product portfolio and market reach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.